This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Labcorp (LH) Tops Q1 Earnings Estimates, Raises 2024 EPS View
by Zacks Equity Research
Labcorp (LH) sets a strong foundation for the year ahead with its impressive performance in the first quarter of 2024.
Chemed (CHE) Lags Q1 Earnings Estimates, Reaffirms 2024 View
by Zacks Equity Research
Chemed's (CHE) first-quarter 2024 results reflect VITAS' impressive revenue growth and improved average revenues per patient per day.
Exact Sciences (EXAS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
by Zacks Equity Research
Thermo Fisher's (TMO) first-quarter 2024 revenues register year-over-year growth driven by new product launches.
Boston Scientific (BSX) Q1 Earnings Beat Estimates, View Raised
by Zacks Equity Research
Barring Neuromodulation, organic and operational revenues at Boston Scientific's (BSX) core business segments rise in the first quarter.
Quest Diagnostics (DGX) Q1 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Quest Diagnostics (DGX) continues its strong momentum of base business revenue growth in the first quarter of 2024.
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XBI
Should You Buy Exact Sciences (EXAS) Ahead of Q1 Earnings?
by Zacks Equity Research
Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.
Here's Why You Should Retain Prestige Consumer (PBH) Stock Now
by Zacks Equity Research
The robust strength of Prestige Consumer's (PBH) diversified portfolio bodes well for investors.
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
by Zacks Equity Research
ICON (ICLR) continues to develop its collaboration and delivery models, invest in technology and enhance its project and program management capabilities.
Why Exact Sciences (EXAS) Dipped More Than Broader Market Today
by Zacks Equity Research
Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.
Abbott (ABT) Q1 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Abbott (ABT) delivers double-digit organic sales growth in its underlying base business in the first quarter of 2024.
Here's Why You Should Retain Henry Schein (HSIC) Stock for Now
by Zacks Equity Research
Favorable Dental business trends and expansion efforts through acquisitions and partnerships bode well for Henry Schein (HSIC).
Myriad Genetics (MYGN) Announces Favorable Research Results
by Zacks Equity Research
Myriad Genetics' (MYGN) latest positive initial study outcome is likely to improve clinical outcomes and reduce overall healthcare costs.
Zacks Investment Ideas feature highlights: Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies
by Zacks Equity Research
Exact Sciences, Kaiser Aluminum and Atmus Filtration Technologies are part of the Zacks Investment Ideas article.
Exact Sciences (EXAS) Stock Moves -0.89%: What You Should Know
by Zacks Equity Research
Exact Sciences (EXAS) closed at $73.60 in the latest trading session, marking a -0.89% move from the prior day.
3 Buy-Rated Stocks Flexing Relative Strength
by Derek Lewis
While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.
Neogen (NEOG) Q3 Earnings Miss Estimates, Gross Margin Expands
by Zacks Equity Research
Neogen's (NEOG) third-quarter fiscal 2024 results reflect solid core revenue growth in both segments.
Exact Sciences' (EXAS) Oncoguard Esophagus Test Looks Promising
by Zacks Equity Research
Exact Sciences (EXAS) advances the development of the non-endoscopic Oncoguard Esophagus test to screen for esophageal cancer and pre-cancer.
Ligand (LGND) Down 15.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
How Much Upside is Left in Exact Sciences (EXAS)? Wall Street Analysts Think 53.83%
by Zacks Equity Research
The mean of analysts' price targets for Exact Sciences (EXAS) points to a 53.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Here's How Much You'd Have If You Invested $1000 in Exact Sciences a Decade Ago
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Exact Sciences (EXAS) Up 4.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM
by Zacks Equity Research
Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.